CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5‐LSD1‐NF‐κB oncogenic signaling-Reference-Cited by-同舟云学术

CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5‐LSD1‐NF‐κB oncogenic signaling

Published:2020-12 Issue:8 Volume:10 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical and Translational Medicine

Author:

Hu Bo¹²,Xu Yang¹²,Li Yuan‐Cheng¹²³,Huang Jun‐Feng⁴,Cheng Jian‐Wen¹²,Guo Wei⁵,Yin Yue¹²,Gao Yang¹²,Wang Peng‐Xiang¹²,Wu Sui‐Yi¹²,Zhou Jian¹²³,Fan Jia¹²³,Yang Xin‐Rong¹²^ORCID

Affiliation:

1. Department of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital, Fudan University Shanghai P.R. China

2. Key Laboratory of Carcinogenesis and Cancer Invasion Ministry of Education Shanghai P. R. China

3. Institutes of Biomedical Sciences Fudan University Shanghai P.R. China

4. Department of Intensive Care Medicine Zhongshan Hospital Fudan University Shanghai P. R. China

5. Department of Laboratory Medicine Zhongshan Hospital Fudan University Shanghai P. R. China

Funder

National Basic Research Program of China

National Natural Science Foundation of China

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.233

Reference42 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)

3. Insights into the success and failure of systemic therapy for hepatocellular carcinoma

4. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

5. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting non-histone methylation in gastrointestinal cancers: From biology to clinic;European Journal of Medicinal Chemistry;2024-11

2. Anlotinib potentiates anti‐PD1 immunotherapy via transferrin receptor‐dependent CD8⁺ T‐cell infiltration in hepatocellular carcinoma;Clinical and Translational Medicine;2024-08

3. Versatile function of NF-ĸB in inflammation and cancer;Experimental Hematology & Oncology;2024-07-16

4. The roles of cancer stem cell-derived secretory factors in shaping the immunosuppressive tumor microenvironment in hepatocellular carcinoma;Frontiers in Immunology;2024-05-29

5. Natural products for combating multidrug resistance in cancer;Pharmacological Research;2024-04